NasdaqGM:KALVBiotechs
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative
KalVista Pharmaceuticals (KALV) closed FY 2025 with fourth quarter revenue of US$59.9 million and a basic EPS loss of US$0.10, alongside net income excluding extra items of a US$5.4 million loss. This provides a clear snapshot of a business still in investment mode. The company has seen quarterly revenue shift from US$13.7 million in FY 2025 Q3 to US$59.9 million in FY 2025 Q4, while basic EPS moved from a US$0.92 loss to a US$0.10 loss over the same period, highlighting a set of results...